Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

UCB's Kygevvi Marks First FDA Approval for Ultra-Rare Mitochondrial Disease

UCB's Kygevvi Marks First FDA Approval for Ultra-Rare Mitochondrial Disease

The U.S. Food and Drug Administration (FDA) has granted approval to UCB's Kygevvi, a groundbreaking therapy for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial disorder. This milestone marks the first-ever approved treatment for TK2d, offering hope to patients with this life-threatening condition.

NoahAI News11/4/2025
Sarepta's Duchenne Drugs Face Setbacks in Confirmatory Trials, Company Pursues Full Approval

Sarepta's Duchenne Drugs Face Setbacks in Confirmatory Trials, Company Pursues Full Approval

Sarepta Therapeutics, a leading player in the Duchenne muscular dystrophy (DMD) treatment landscape, is facing significant challenges as its key drugs fail to meet primary endpoints in confirmatory trials. Despite these setbacks, the company is pushing forward with plans to seek full approval for its treatments, citing real-world evidence and pandemic-related complications as mitigating factors.

NoahAI News11/4/2025
Merck's Strategic Moves: $700M Blackstone Deal and $150M Asset Acquisition

Merck's Strategic Moves: $700M Blackstone Deal and $150M Asset Acquisition

Merck & Co. has made significant strides in the pharmaceutical industry with two major deals announced on Tuesday. The company has secured $700 million in funding from Blackstone Life Sciences to support its oncology program while also spending $150 million to regain full control of an early-phase asset.

NoahAI News11/4/2025
Teva Issues Massive Recall of Blood Pressure Medication Due to Carcinogen Concerns

Teva Issues Massive Recall of Blood Pressure Medication Due to Carcinogen Concerns

Pharmaceutical giant Teva has initiated a significant voluntary recall of its widely prescribed blood pressure medication, prazosin hydrochloride, due to the presence of potentially cancer-causing impurities. The recall, announced on October 7, affects over half a million bottles and highlights ongoing challenges in the pharmaceutical industry regarding drug safety and manufacturing processes.

NoahAI News11/4/2025
Vertex's Q3 Results: Mixed Performance Across Key Products

Vertex's Q3 Results: Mixed Performance Across Key Products

Vertex Pharmaceuticals, a leading player in the pharmaceutical industry, has reported its third-quarter results for 2025, revealing a complex landscape of successes and challenges across its product portfolio. The company's performance, particularly in its newer offerings, has drawn attention from investors and analysts alike.

NoahAI News11/4/2025
Neok Bio Emerges with $75M to Develop Dual-Targeting Antibody-Drug Conjugates

Neok Bio Emerges with $75M to Develop Dual-Targeting Antibody-Drug Conjugates

Neok Bio, a new player in the biotechnology arena, has launched with a substantial $75 million Series A funding round to advance its innovative approach to antibody-drug conjugates (ADCs). The company aims to overcome limitations of conventional ADCs by developing "bispecific" versions that simultaneously target two cancer-related proteins.

NoahAI News11/4/2025
Nuvation Bio Shifts Strategy for Brain Cancer Drug Development

Nuvation Bio Shifts Strategy for Brain Cancer Drug Development

Nuvation Bio, a prominent player in the pharmaceutical industry, has announced a significant change in its clinical development plans for safusidenib, its brain-penetrant mIDH1 inhibitor. This shift comes in response to discussions with the U.S. Food and Drug Administration (FDA) and marks a new direction in the company's approach to treating brain cancer.

NoahAI News11/4/2025
Celltrion Expands Beyond Biosimilars with $744M Deal for Autoimmune Drug Candidates

Celltrion Expands Beyond Biosimilars with $744M Deal for Autoimmune Drug Candidates

Korean biosimilar specialist Celltrion has entered into a significant agreement with U.S. biotech Kaigene, potentially worth over $740 million, for two preclinical autoimmune assets. This move marks a strategic shift for Celltrion as it looks to diversify its portfolio beyond biosimilars.

NoahAI News11/4/2025
Pfizer's Shelved Compound Becomes Breakthrough Treatment for Rare Disease

Pfizer's Shelved Compound Becomes Breakthrough Treatment for Rare Disease

In a remarkable turn of events, a once-abandoned pharmaceutical compound has emerged as a groundbreaking treatment for a rare genetic disorder, highlighting the untapped potential within major drug companies' pipelines. The story of mirdametinib, now known as Gomekli, serves as a powerful example of how corporate leadership and patient advocacy can breathe new life into forgotten therapies.

NoahAI News11/4/2025
FDA Drug Regulator Resigns Amid Personal Conduct Investigation, Then Reconsiders

FDA Drug Regulator Resigns Amid Personal Conduct Investigation, Then Reconsiders

In a surprising turn of events, George Tidmarsh, the director of the FDA's Center for Drug Evaluation and Research, has resigned from his position amid an ongoing investigation into his personal conduct. However, less than 24 hours after tendering his resignation, Tidmarsh reportedly reconsidered his decision, vowing to fight for his name and credibility.

NoahAI News11/4/2025
Neurocrine Biosciences Expands Pipeline with $881M NLRP3 Inhibitor Deal

Neurocrine Biosciences Expands Pipeline with $881M NLRP3 Inhibitor Deal

Neurocrine Biosciences, a San Diego-based biopharmaceutical company, has entered into a licensing agreement with China's TransThera Sciences for the development and commercialization of NLRP3 inhibitors. The deal, potentially worth up to $881.5 million, marks Neurocrine's strategic move to diversify its pipeline and tap into the growing field of inflammasome-targeted therapies.

NoahAI News11/4/2025
Pharmaceutical Industry Faces Widespread Layoffs and Restructuring Amid Challenging Market Conditions

Pharmaceutical Industry Faces Widespread Layoffs and Restructuring Amid Challenging Market Conditions

The pharmaceutical and biotech industries are experiencing a significant wave of layoffs and restructuring efforts as companies grapple with challenging market conditions, pipeline setbacks, and the need to reallocate resources. Major players and smaller biotechs alike are trimming their workforces to extend cash runways and focus on priority programs.

NoahAI News11/4/2025
«1...444546...67»